Head and Neck Chemotherapy Regimens

The information contained in these regimens is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. The treatment regimen to be used should take into account factors such as histology, molecular pathology, age, performance status, co-morbidities and the patient’s preference. Each treatment regimen has advantages and disadvantages, and there may be more than one good option.  In addition, treatment choices can change over time as more evidence becomes available.Use of these documents is the responsibility of the prescribing clinician and is subject to the HSE.ie terms of use.

Please email any comments or feedback on these regimens to oncologydrugs@cancercontrol.ie

Head and Neck Chemotherapy protocols

 
Regimen Name Indication

Carboplatin AUC (1.5) Chemoradiation Therapy-7 days

Regimen

00332a*

Chemoradiation commencing 3 to 8 weeksafter the completion of induction chemotherapy with TPF in patients with Stage III or IV locally advanced squamous cell carcinoma (SCC) of the head and neck. 

Carboplatin (AUC2) Weekly with Radiotherapy (RT)

Regimen

00419

Chemoradiation treatment of stage III and IV locally advanced nasopharyngeal carcinoma in patients where CISplatin is contraindicated or not tolerated.

Cetuximab (weekly), Carboplatin AUC 5 and 5-FU 1000mg/m2/day

Regimen


00418a

Locally advanced or metastatic squamous cell head and neck cancer where CISplatin is contraindicated or not tolerated

Cetuximab (weekly), CISplatin 100mg/m2 and 5-FU 1000mg/m2/day Therapy-21 day cycle

Regimen

00417a

Locally advanced or metastatic squamous cell carcinoma of the head and neck

Cetuximab Therapy- 7 days

Regimen

00207b

Treatment of patients with squamous cell cancer of the head and neck: In combination with radiation therapy for locally advanced disease.

CISplatin 40mg/m2 Weekly with Radiotherapy (RT)

Regimen

00385c

Chemoradiation treatment for locally advanced nasopharnygeal carcinoma.

00385d

Chemoradiation treatment for locally advanced unresectable head and neck squamous carcinoma (SCC) in patients who cannot tolerate three weekly CISplatin regimens.

CISplatin 100mg/m2 with Radiotherapy (RT)

Regimen

00387a

Chemoradiation treatment for locally advanced (stage III to IV) squamous cell carcinoma (SCC) of the head and neck.

Cisplatin and 5-FU Therapy

Regimen

00314a

Locally advanced or metastatic head and neck cancer.

Neoadjuvant Docetaxel/Cisplatin/5-FU + Chemoradiation + Surgery

Regimen

00315a

Induction treatment of patients with Stage III or IV non-metastatic squamous cell carcinoma of the head and neck.

Docetaxel/Cisplatin/5-FU + Chemoradiation

Regimen

00323a

Induction treatment of patients with locally advanced Stage III or IV non-metastatic squamous cell carcinoma of the head and neck.

Docetaxel/Cisplatin/5-FU + Radiotherapy

Regimen

00324a

Induction treatment followed by radiotherapy of patients with Stage III or IV non-metastatic squamous cell carcinoma of the head and neck.

Lenvatinib Therapy

Regimen

00295a

Treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine.

Sorafenib Therapy

Regimen

00294c

Treatment of patients with progressive, locally advanced or metastatic differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.

Vandetanib Monotherapy

Regimen

00242a

Treatment of aggressive and symptomatic MTC in patients with unresectable locally advanced or metastatic disease

 * Unlicensed indication. See protocol for more details.